ACT 280778

Drug Profile

ACT 280778

Alternative Names: ACT-280778

Latest Information Update: 24 Apr 2012

Price : $50

At a glance

  • Originator Actelion Pharmaceuticals
  • Class Antihypertensives
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Essential hypertension

Most Recent Events

  • 19 Apr 2012 Discontinued - Phase-II for Essential hypertension in Israel (PO)
  • 19 Apr 2012 Discontinued - Phase-II for Essential hypertension in Serbia (PO)
  • 23 Feb 2011 Phase-II clinical trials in Essential hypertension in Serbia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top